Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. S...
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Investigation of Early Hormonotherapy Efficacy of Prostate Cancer
- Conditions
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Kaunas University of Medicine
- Target Recruit Count
- 61
- Registration Number
- NCT00375687
- Locations
- 🇱🇹
Urology dep. of Kaunas University of Medicine, Kaunas, Lithuania
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 280
- Registration Number
- NCT00311636
- Locations
- 🇮🇹
Ospedale Civile, Castelfranco - TV, Italy
🇮🇹Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
🇮🇹Ospedale Sant Anna, Como, Italy
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 378
- Registration Number
- NCT00104741
- Locations
- 🇫🇷
Centre Hospital Regional Universitaire de Limoges, Limoges, France
🇫🇷Centre Hospitalier Universitaire Henri Mondor, Creteil, France
🇫🇷Clinique De Rochebelle, Ales, France
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
- First Posted Date
- 2004-09-08
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 49
- Registration Number
- NCT00090844
- Locations
- 🇺🇸
MBCCOP - JHS Hospital of Cook County, Chicago, Illinois, United States
🇺🇸MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-12-09
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- St. Luke's Hospital, Ireland
- Target Recruit Count
- 276
- Registration Number
- NCT00003734
- Locations
- 🇮🇪
Cork University Hospital, Cork, Ireland
🇮🇪Letterkenny Hospital, Donnegal, Ireland
🇮🇪St. Vincent's Hospital, Dublin, Ireland
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 2672
- Registration Number
- NCT00066703
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Premenopausal Endocrine Responsive Chemotherapy Trial
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 29
- Registration Number
- NCT00066807
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Kantonsspital - St. Gallen, St. Gallen, Switzerland
🇮🇹Centro di Riferimento Oncologico - Aviano, Aviano, Italy
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 3066
- Registration Number
- NCT00066690
- Locations
- 🇺🇸
Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Finley Hospital, Dubuque, Iowa, United States
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 966
- Registration Number
- NCT00003026
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇬🇧City General Hospital, Stoke-On-Trent, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.